- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00469859
Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Pilot Study of Lestaurtinib (CEP-701) in Combination With Chemotherapy in Young Patients With Relapsed or Refractory FLT3-mutant Acute Myeloid Leukemia
RATIONALE: Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine and idarubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lestaurtinib together with cytarabine and idarubicin may kill more cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of lestaurtinib when given together with cytarabine and idarubicin and to see how well they work in treating younger patients with relapsed or refractory acute myeloid leukemia.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Determine a safe, tolerable, and biologically active dose of lestaurtinib in combination with chemotherapy comprising cytarabine and idarubicin in younger patients with relapsed or refractory FLT3-mutant acute myeloid leukemia.
Secondary
- Determine the overall response rate in patients treated with this regimen.
- Optimize dosing of lestaurtinib based primarily on biologic activity rather than toxicity.
- Correlate the clinical response to this regimen with the ability to achieve adequate FLT3 plasma inhibitory activity levels and the in vitro sensitivity of pretreatment leukemic cells to lestaurtinib in these patients.
- Determine the mechanisms of resistance to lestaurtinib in these patients.
- Assess the feasibility of using rapid central determination of FLT3 mutation status at study entry to determine induction therapy in future upfront protocols.
OUTLINE: This is a multicenter, dose-finding study of lestaurtinib followed by an efficacy study.
Dose-finding phase:
- Course 1: Patients receive cytarabine IV over 2 hours twice daily on days 1-4, idarubicin IV over 15 minutes on days 2-4, and oral lestaurtinib twice daily on days 5-28. Patients achieving complete or partial response proceed to course 2.
Cohorts of 6 patients receive escalating doses of lestaurtinib until a tolerable and biologically active dose (TBAD) is determined. The TBAD is defined as the dose at which no more than 2 of 6 patients experience DLT and biologic activity is confirmed by plasma inhibitory activity (PIA) assay.
- Course 2: Patients receive high-dose cytarabine IV over 3 hours twice daily on days 1-4 and oral lestaurtinib (at the dose determined in course 1) twice daily on days 5-28. Patients achieving complete or partial response proceed to continuation therapy.
Continuation therapy: Patients receive oral lestaurtinib twice daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
- Efficacy phase: Once the TBAD is determined, subsequent patients receive treatment as in course 1 and 2 with lestaurtinib at the TBAD. Patients may also receive continuation therapy as in the dose-finding phase.
Blood samples are collected periodically during study treatment for pharmacokinetic and PIA assays.
After completion of study treatment, patients are followed periodically for up to 5 years.
PROJECTED ACCRUAL: A total of 37 patients will be accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham
-
-
California
-
Orange, California, United States, 92868
- Children's Hospital of Orange County
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010-2970
- Children's National Medical Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Winship Cancer Institute of Emory University
-
-
Illinois
-
Chicago, Illinois, United States, 60614
- Children's Memorial Hospital - Chicago
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202-5289
- Indiana University Melvin and Bren Simon Cancer Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21231-2410
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109-0286
- C.S. Mott Children's Hospital at University of Michigan Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Masonic Cancer Center at University of Minnesota
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
-
-
New York
-
New York, New York, United States, 10032
- Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229-3039
- Cincinnati Children's Hospital Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97239-3098
- Knight Cancer Institute At Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104-9786
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, United States, 15213
- Children's Hospital of Pittsburgh
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Children's Research Hospital
-
Nashville, Tennessee, United States, 37232-6838
- Vanderbilt-Ingram Cancer Center
-
-
Texas
-
Dallas, Texas, United States, 75390
- Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
-
Houston, Texas, United States, 77030-2399
- Baylor University Medical Center - Houston
-
-
Washington
-
Seattle, Washington, United States, 98105
- Children's Hospital and Regional Medical Center - Seattle
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Diagnosis of acute myeloid leukemia (AML) according to FAB classification
- At least 5% blasts in the bone marrow, with or without extramedullary disease
In first relapse after induction therapy OR refractory to induction therapy with ≤ 1 attempt at remission induction
- Patients who are in a first relapse > 1 year from their initial diagnosis of AML are excluded from the dose-finding phase of the study, but are eligible for the efficacy phase
- First relapse after hematopoietic stem cell transplantation (HSCT) allowed provided patient has no evidence of active graft-versus-host disease (GVHD) and is at least 4 months posttransplantation
- Positive for a FLT3 activating mutation (internal tandem duplication or kinase domain point mutation) using standard polymerase chain reaction-based procedures at any time in the course of illness
- Treatment-related AML allowed
PATIENT CHARACTERISTICS:
- Karnofsky performance status (PS) 50-100% (> 16 years of age) OR Lansky PS 50-100% (≤ 16 years of age)
Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR serum creatinine based on age and gender as follows:
- Creatinine no greater than 0.4 mg/dL (1 month to < 6 months of age)
- Creatinine no greater than 0.5 mg/dL (6 months to < 1 year of age)
- Creatinine no greater than 0.6 mg/dL (1 year to < 2 years of age)
- Creatinine no greater than 0.8 mg/dL (2 years to < 6 years of age)
- Creatinine no greater than 1 mg/dL (6 years to < 10 years of age)
- Creatinine no greater than 1.2 mg/dL (10 years to < 13 years of age)
- Creatinine no greater than 1.4 mg/dL (females) or 1.5 mg/dL (males) (13 years to < 16 years of age)
- Creatinine no greater than 1.4 mg/dL (females) or 1.7 mg/dL (males) (16 years of age and over)
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- ALT < 5 times ULN (unless it is related to leukemic involvement)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Shortening fraction ≥ 27% by echocardiogram OR ejection fraction ≥ 50% by radionuclide angiogram
PRIOR CONCURRENT THERAPY:
- Recovered from all prior therapy
No prior cumulative anthracycline doses exceeding 450 mg/m^2 daunorubicin equivalents
- Patients who relapse after receiving treatment on protocol COG-AAML03P1 or COG-AAML0531 (300 mg/m^2 of daunorubicin hydrochloride and 48 mg/m^2 of mitoxantrone hydrochloride) allowed provided they have not received any additional anthracyclines
At least 14 days since prior cytotoxic therapy
- Hydroxyurea allowed to decrease the WBC prior to starting protocol treatment
- No concurrent hydroxyurea
- At least 7 days since prior biologic agents
- At least 14 days since prior monoclonal antibody therapy
Radiotherapy to chloromas allowed
- Irradiated lesion may not be used to assess tumor response
No other concurrent chemotherapy, investigational therapy, immunomodulating agents, or steroids
- Steroids used as an antiemetic allowed
- Prophylactic intrathecal cytarabine allowed
No concurrent CYP3A4,5 inhibitors, including any of the following:
- Azole antifungals (e.g., fluconazole or voriconazole)
- Cyclosporine
- Erythromycin
- Clarithromycin
- Troleandomycin
- HIV protease inhibitors
- Nefazodone
No concurrent CYP3A4,5 inducers, including any of the following:
- Carbamazepine
- Dexamethasone
- Rifampin
- Phenobarbital
- Phenytoin
- Hypericum perforatum (St. John's wort)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1 (Lestaurtinib dose 50 mg/m2
DOSE-FINDING PHASE: COURSE 1: Patients receive cytarabine IV over 2 hours twice daily on days 1-4, idarubicin IV over 15 minutes on days 2-4, and oral lestaurtinib twice daily on days 5-28. Patients achieving complete or partial response proceed to course 2. Cohorts of 6 patients receive escalating doses of lestaurtinib until a TBAD is determined. The TBAD is defined as the dose at which no more than 2 of 6 patients experience DLT and biologic activity is confirmed by PIA assay. COURSE 2: Patients receive high-dose cytarabine IV over 3 hours twice daily on days 1-4 and oral lestaurtinib (at the dose determined in course 1) twice daily on days 5-28. Patients achieving complete or partial response proceed to continuation therapy. CONTINUATION THERAPY: Patients receive oral lestaurtinib twice daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Continued (see detailed description) |
Given IV
Other Names:
given IV
Other Names:
Given orally
Other Names:
|
Experimental: Group 2 (Lestaurtinib: Dose 62.5 mg/m2
DOSE-FINDING PHASE: COURSE 1: Patients receive cytarabine IV over 2 hours twice daily on days 1-4, idarubicin IV over 15 minutes on days 2-4, and oral lestaurtinib twice daily on days 5-28. Patients achieving complete or partial response proceed to course 2. Cohorts of 6 patients receive escalating doses of lestaurtinib until a TBAD is determined. The TBAD is defined as the dose at which no more than 2 of 6 patients experience DLT and biologic activity is confirmed by PIA assay. COURSE 2: Patients receive high-dose cytarabine IV over 3 hours twice daily on days 1-4 and oral lestaurtinib (at the dose determined in course 1) twice daily on days 5-28. Patients achieving complete or partial response proceed to continuation therapy. CONTINUATION THERAPY: Patients receive oral lestaurtinib twice daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Continued (see detailed description) |
Given IV
Other Names:
given IV
Other Names:
Given orally
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-limiting Toxicity
Time Frame: 28 days
|
Number of patients with dose-limiting toxicity (DLT)
|
28 days
|
>80% Inhibition of FLT3 Phosphorylation in a Majority of Post-treatment Trough Time Points
Time Frame: Course 1 day 7, day 14, day 21, and day 28.
|
FLT3 inhibition is determined in patients receiving lestaurtinib by measuring FLT3 plasma inhibitory activity (PIA).
For PIA predictive modeling, a random effects linear regression model will be used to describe the relationship between PIA and Pharmacokinetic (PK) levels for each of the 5 trough plasma samples collected for each patient
|
Course 1 day 7, day 14, day 21, and day 28.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Patrick A. Brown, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study Chair: Donald Small, MD, PhD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- adult acute myeloid leukemia with 11q23 (MLL) abnormalities
- adult acute myeloid leukemia with inv(16)(p13;q22)
- adult acute myeloid leukemia with t(15;17)(q22;q12)
- adult acute myeloid leukemia with t(16;16)(p13;q22)
- adult acute myeloid leukemia with t(8;21)(q22;q22)
- secondary acute myeloid leukemia
- recurrent adult acute myeloid leukemia
- recurrent childhood acute myeloid leukemia
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Cytarabine
- Idarubicin
Other Study ID Numbers
- AAML06P1
- CDR0000543398 (Other Identifier: Clinical Trials.gov)
- COG-AAML06P1 (Other Identifier: Children's Oncology Group)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia
-
Stanford UniversityTerminatedLeukemia | Leukemia, Lymphocytic, Acute | Leukemia Acute Promyelocytic Leukemia (APL) | Leukemia Acute Lymphoid Leukemia (ALL) | Leukemia Chronic Myelogenous Leukemia (CML) | Leukemia Acute Myeloid Leukemia (AML) | Leukemia Chronic Lymphocytic Leukemia (CLL)United States
-
Massachusetts General HospitalCelgene CorporationTerminatedAcute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic LeukemiaUnited States
-
Institute of Hematology & Blood Diseases HospitalBejing Institute for Stem Cell and Regenerative Medicine; Institute for Stem...RecruitingRefractory Leukemia | Relapsed Leukemia | Acute Myeloid Leukemia, ChildhoodChina
-
Betta Pharmaceuticals Co., Ltd.Not yet recruitingAcute Myeloid Leukemia LeukemiaChina
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
-
Hybrigenics CorporationUnknownAcute Myelogenous LeukemiaUnited States, France
-
Center for International Blood and Marrow Transplant...National Marrow Donor Program; St. Baldrick's FoundationActive, not recruitingAcute Myelogenous LeukemiaUnited States
-
Massachusetts General HospitalCompleted
-
Beijing Boren HospitalRecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapse LeukemiaChina
-
National Cancer Institute (NCI)TerminatedAdult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditionsUnited States
Clinical Trials on idarubicin
-
The Affiliated Hospital of the Chinese Academy...UnknownAcute Myeloid LeukemiaChina
-
Clavis PharmaSyneos Health; TheradexCompletedAcute Myeloid LeukemiaUnited States, Norway, Germany, France
-
Zhongda HospitalRecruiting
-
University Hospital, MontpellierGuerbetRecruiting
-
Federation Francophone de Cancerologie DigestiveCompleted
-
University Hospital, MontpellierCompleted
-
Groupe Francophone des MyelodysplasiesCompletedHigh Grade Myelodysplastic Syndrome LesionsFrance, Tunisia
-
Centre Hospitalier Universitaire DijonCompletedCarcinoma, HepatocellularFrance
-
Acute Leukemia French AssociationAssistance Publique - Hôpitaux de ParisTerminatedAcute Myeloid LeukemiaFrance
-
OnxeoCompletedAcute Myeloid LeukemiaUnited Kingdom, Germany, France